Erelzi™

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, solution
• Subcutaneous
• Colourless to slightly yellowish solution. Clear to slightly opalescent solution.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1 pre-filled syringe containing 0.5 mL solution
• 12 pre-filled syringes each containing 0.5 mL solution
• 2 pre-filled syringes each containing 0.5 mL solution
• 4 pre-filled syringes each containing 0.5 mL solution

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: etanercept

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).